The Drug Enforcement Administration (DEA) announced last Friday that certain Food and Drug Administration (FDA)-approved drugs that contain cannabidiol (CBD) are properly rescheduled as Schedule V drugs under the Controlled Substances Act (CSA). While this move is far from categorically rescheduling CBD – as only...

As you may be aware, Cultiva Law is committed to advancing social justice issues as well as representing the cannabis industry, and one of Cultiva Law's primary issues of focus from a policy standpoint is easing the process by which people can vacate qualifying criminal records,...

In our previous post, we discussed general rules applicable to the transportation of cannabis both across and within state lines. Here, we discuss the issue of who is responsible when an accident happens – or worse, an intentional wrongful act is committed – by an...

Some of the most commonly asked questions by cannabis business owners and operators, as well as consumers, involve the transportation of marijuana and the applicable laws, as well as the division of liability between the business owner and the driver. Transportation of marijuana is highly regulated....

Cultiva's own Aaron Pelley was recently featured in the Spokesman-Review for his selection as a Featured Speaker at this year's upcoming Seattle Hempfest. Aaron Pelley will be featured at Hempfest's 27th annual "protestival" held in Myrtle Edwards Park and Elliot Bay Park on August 17, 18, and 19, 2018....

Cannabis industry insiders recently learned the Washington State Liquor and Cannabis Board (WSLCB) is considering implementing a “Hidden Ownership Amnesty Program” that would allow cannabis businesses to come into compliance with ownership and financing regulations without fear of license revocation. In this article, we dive...

By: Sam Mendez, Strategic Legal Counsel at Cultiva Law The Washington State Liquor and Cannabis Board (WSLCB) recently proposed a “Hidden Ownership Amnesty Program” at their June 27, 2018 Executive Management Team meeting. Insiders learned about this development after a transcript (see p. 5) was written up by a team...

Contact Us For A Consultation

Call (888) 896-3313 or fill out the form below: